4.6 Review

Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures

期刊

MOLECULES
卷 22, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/molecules22122070

关键词

aptamers; Cell-SELEX; aptamer enrichment; ssDNA; binding assays

资金

  1. Department of Health (Merit Award)
  2. Western Australian Government
  3. McCusker Charitable Foundation
  4. Perron Institute for Neurological and translations Science

向作者/读者索取更多资源

Systematic evolution of ligands by exponential enrichment (SELEX) is an established procedure for developing short single-stranded nucleic acid ligands called aptamers against a target of choice. This approach has also been used for developing aptamers specific to whole cells named Cell-SELEX. Aptamers selected by Cell-SELEX have the potential to act as cell specific therapeutics, cell specific markers or cell specific drug delivery and imaging agents. However, aptamer development is a laborious and time-consuming process which is often challenging due to the requirement of frequent optimization of various steps involved in Cell-SELEX procedures. This review provides an insight into various procedures for selection, aptamer enrichment, regeneration and aptamer-binding analysis, in addition to a very recent update on all aptamers selected by Cell-SELEX procedures.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?

Michelle Bauer, Mia Strom, David S. Hammond, Sarah Shigdar

MOLECULES (2019)

Article Biochemistry & Molecular Biology

Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells

Joanna Macdonald, Delphine Denoyer, Justin Henri, Adelaide Jamieson, Ingrid J. G. Burvenich, Normand Pouliot, Sarah Shigdar

NUCLEIC ACID THERAPEUTICS (2020)

Article Medicine, Research & Experimental

Development of a Novel DNA Oligonucleotide Targeting Low-Density Lipoprotein Receptor

Tao Wang, Kamal Rahimizadeh, Rakesh N. Veedu

MOLECULAR THERAPY-NUCLEIC ACIDS (2020)

Review Biochemistry & Molecular Biology

Antibodies, Nanobodies, or Aptamers-Which Is Best for Deciphering the Proteomes of Non-Model Species?

Poshmaal Dhar, Rasika M. Samarasinghe, Sarah Shigdar

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Genetics & Heredity

Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human MAPT Gene Expression

Madhuri Chakravarthy, Suxiang Chen, Tao Wang, Rakesh N. Veedu

Review Biochemistry & Molecular Biology

Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery

Bakhtiar Bukari, Rasika M. Samarasinghe, Jinjutha Noibanchong, Sarah L. Shigdar

BIOMEDICINES (2020)

Review Biochemistry & Molecular Biology

Novel Detection of Nasty Bugs, Prevention Is Better than Cure

Mia Strom, Tamsyn Crowley, Sarah Shigdar

Summary: Hospital-acquired infections (HAIs) are a growing concern globally, with bacteria being the most common cause and highly resistant to antibiotics. Detecting and eradicating bacteria in the environment can reduce infection rates effectively.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Correction Multidisciplinary Sciences

Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells (vol 7, pg 5898, 2017)

Hadi AlShamaileh, Tao Wang, Dongxi Xiang, Wang Yin, Phuong Ha-Lien Tran, Roberto A. Barrero, Pei-Zhuo Zhang, Yong Li, Lingxue Kong, Ke Liu, Shu-Feng Zhou, Yingchun Hou, Sarah Shigdar, Wei Duan

SCIENTIFIC REPORTS (2020)

Review Biochemistry & Molecular Biology

Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach

Chris Vi, Giovanni Mandarano, Sarah Shigdar

Summary: Breast cancer, a common cancer in women, exhibits high heterogeneity. Overexpression of HER2 is strongly associated with poor outcomes of breast cancer. Molecular imaging offers sensitive detection for early diagnosis, crucial for improving prognosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Biotechnology & Applied Microbiology

Aptamers: Cutting edge of cancer therapies

Sarah Shigdar, Brett Schrand, Paloma H. Giangrande, Vittorio de Franciscis

Summary: The development of aptamer-based therapeutics has rapidly progressed, with eleven aptamers entering clinical trials for various therapeutic indications. Despite some success in pre-clinical and clinical studies, no aptamer has been FDA-approved for cancer treatment. Recent research focuses on enhancing anti-cancer immunity, targeting hard-to-treat cancers, and developing carrier aptamers for delivering RNA therapeutics.

MOLECULAR THERAPY (2021)

Review Pharmacology & Pharmacy

Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options

Maryam Nakhjavani, Rasika M. Samarasinghe, Sarah Shigdar

Summary: The key challenges in treating triple-negative breast cancer brain metastasis (TNBC-BM) lie in the absence of targeted therapy and difficulties in delivering drugs to the brain. This review introduces current drugs based on their molecular targets and seeks to improve drug delivery to the brain using more efficient and promising drug delivery systems. Ongoing clinical trials on druggable targets in TNBC-BM are described to achieve more targeted treatment, along with an introduction to the obstacles hindering drug delivery to the brain and strategies for future advancements in TNBC-BM patient treatment.

DRUG DISCOVERY TODAY (2022)

Article Pharmacology & Pharmacy

Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer

Maryam Nakhjavani, Sarah Shigdar

Summary: Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes and lacks targeted therapy. Immunotherapy targeting PD-1/PD-L1 has shown promise. Aptamers, with their better tissue penetration and lower production cost compared to mAbs, present a potential pathway for PD-1/PD-L1 modulation in the future.

PHARMACOLOGICAL RESEARCH (2022)

Review Pharmacology & Pharmacy

Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof

Sarah Shigdar, Lisa Agnello, Monica Fedele, Simona Camorani, Laura Cerchia

Summary: The identification of tumor cell-specific surface markers is crucial for personalized cancer medicine. Currently, the repertoire of approved treatments targeting cell membrane is limited, resulting in the inability to treat many cancers. Cell-SELEX technology provides a valid complement to existing strategies for biomarkers' discovery and has the potential to increase the number of cancer cell-surface biomarkers.

PHARMACEUTICS (2022)

Article Pharmacology & Pharmacy

Modelling of mass transport and distribution of aptamer in blood-brain barrier for tumour therapy and cancer treatment

Mohsen Sarafraz, Maryam Nakhjavani, Sarah Shigdar, Farid C. Christo, Bernard Rolfe

Summary: The blood-brain barrier is a major obstacle in brain cancer treatment, but targeting transferrin receptors using aptamers can increase drug delivery. The thickness of the astrocyte and endothelial cell layers is identified as a key parameter affecting drug concentration. The drug delivery mechanism switches from convective mass transport to mixed convection mass transport and finally to diffusion as it reaches the brain parenchyma.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2022)

Review Chemistry, Medicinal

Radiolabelled Aptamers for Theranostic Treatment of Cancer

Umair Khalid, Chris Vi, Justin Henri, Joanna Macdonald, Peter Eu, Giovanni Mandarano, Sarah Shigdar

PHARMACEUTICALS (2019)

暂无数据